Bringing the Oncology Community Together
View more videos >>
Dr. O’Regan Discusses Updates in HER2-Positive Breast Cancer
Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC
Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients
Dr. Carlson on Treating Breast Cancer Patients Under 40
View more articles >>
Changing Trends in Prostate Cancer Therapy: Is Earlier Better?
Although the incidence and mortality of prostate cancer remain formidable problems in the United States, clinicians have many new agents with proven overall survival (OS) benefits to recommend for patients with metastatic disease.
Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC
Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.
OncLive Adds Winship Cancer Institute of Emory University to its Strategic Alliance Partnership Program
OncLive will work with Georgia’s only NCI-designated cancer center to support its efforts to conduct innovative, multidisciplinary research and translate that knowledge into excellent patient care.
New Drug Class Shows Activity in Refractory Multiple Myeloma
The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.
Tweets by @WinshipAtEmory
Tweets by @OncLive
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.